Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
P26885

UPID:
FKBP2_HUMAN

ALTERNATIVE NAMES:
13 kDa FK506-binding protein; FK506-binding protein 2; Immunophilin FKBP13; Rotamase

ALTERNATIVE UPACC:
P26885; Q5BJH9; Q9BTS7

BACKGROUND:
The protein Peptidyl-prolyl cis-trans isomerase FKBP2, known by alternative names such as 13 kDa FK506-binding protein and Immunophilin FKBP13, is integral to the protein folding process. It achieves this by catalyzing the cis-trans isomerization of proline imidic peptide bonds, a critical step for achieving the correct conformation of proteins.

THERAPEUTIC SIGNIFICANCE:
Exploring the functionalities of Peptidyl-prolyl cis-trans isomerase FKBP2 offers a promising avenue for drug discovery. Given its essential role in protein folding, targeting this protein could lead to innovative treatments for diseases where protein misfolding is a contributing factor.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.